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Immunotherapeutics include drugs and biologics that render therapeutic benefit by harnessing the power of the
immune system. The promise of immune-mediated therapies is target specificity with a consequent reduction in
off-target side effects. Recent scientific advances have led to clinical trials of both active and passive
immunotherapeutic products that have the potential to convert life-ending diseases into chronic but manageable
conditions. Clinical trials investigating immunotherapeutics are ongoing with some trials at advanced stages of
development. However, as with many products involving novel mechanisms of action, major regulatory and
scientific issues arising with clinical use of immunotherapeutic products remain to be addressed. In this review, we
address issues related to different immunotherapeutics and provide recommendations for the characterization and
evaluation of these products during various stages of product and clinical development.Introduction
Since Coley’s observation in the 19th century that some
tumors respond to infectious challenges with streptococ-
cus bacteria, medical science has been searching for a
way to activate the immune system against cancer [1].
Coley's early studies eventually led to cancer immuno-
therapy using Bacillus Calmette-Guérin (BCG), which is
still used to treat superficial bladder cancer [2].
Immunotherapeutic products can be classified broadly
under (1) active immunotherapy (therapeutic vaccines),
(2) adoptive cellular immunotherapy (transfer of
immune cells [T and B cell therapies] or precursor cells
[autologous or allogenic stem cell therapies] or the
transfer of gene modified autologous or allogenic cells
[Chimeric CAR/TCR engineered T cells]) or (3) passive
immunotherapy (administration of antibody or receptor/
ligand). These approaches are based on prior preclinical
and clinical knowledge, as well as current understanding
of immunology.* Correspondence: Raj.Puri@fda.hhs.Gov
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reproduction in any medium, provided the orOf these three broad categories of immunotherapeutic
products, adoptive cellular immunotherapy products are
the most recent to show early signs of benefit and thera-
peutic value to the patient population [3]. The appeal of
immune-mediated therapies is target specificity, with
minimization of off-target side effects. However, immune-
mediated therapies, which are intended to direct the
immune system to counter tumors expressing certain
tumor-associated antigens (TAA), may also induce a
response to antigens that are expressed by normal tissues.
Thus testing in appropriate preclinical studies is important
to evaluate the safety of immune-mediated therapies.
Some approaches to overcoming these challenges include
developing a better understanding of the investigational
immunotherapy products and their mechanism of action.
The Food and Drug Administration (FDA) regulates
drugs and biologics under the authority granted to it by
the Federal Food, Drug, and Cosmetic Act (FD&C Act,
1938) and its amendments [4].
Under this authority, FDA regulates the pre-market
testing and marketing approval for all immunotherapeutic
agents, either as drugs or biologics depending on theLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Immunotherapeutic products that are regulated as bio-
logics include antibodies and proteins and some nucleic
acids. Other immunotherapeutic products that are
biologics include live immunological cellular products
(dendritic cells, T cells, etc., or their precursors [e.g., cord
blood cells, adult stem cells], or cellular products pulsed
with peptides), peptides or proteins acting as or mimick-
ing tumor antigens to induce or boost a specific host
immune response, and gene therapy products 1 (bacterial,
viral and plasmid vectors, mRNAs, siRNAs, miRNAs,
antisense RNAs, etc.). Immunotherapeutic products are
regulated by the FDA under the purview of the Center for
Biologics Evaluation and Research (CBER) Office of
Cellular, Tissue and Gene Therapies (OCTGT) and by the
Center for Drug Evaluation and Research (CDER), Office
of Hematology and Oncology Products (OHOP) and
Office of Biotechnology Products (OBP).
CDER is responsible for the review of monoclonal anti-
bodies and proteins which are administered directly to pa-
tients for therapeutic intervention. These products include
cytokines, (e.g., interferons), enzymes (e.g., thrombolytics),
toxins, and all other proteins, except for those that are
specifically assigned to CBER (e.g., vaccines and blood
products). In addition, CDER is also responsible for the
review of immunomodulators (non-vaccines and non-
allergenic products intended to treat disease by inhibiting
or modifying a pre-existing immune response).
CBER/OCTGT is responsible for the review of cancer
vaccines and cell-based immunotherapeutic products.
These products include dendritic cells, activated T
lymphocytes (e.g., TIL, LAK), B cells, monocytes, cancer
cells (chemically modified or unmodified), gene therapy
products including ex vivo gene-modified cells, proteins
and peptides as tumor antigens, either alone or mixed
with adjuvants (e.g., KLH, BCG, GM-CSF), idiotypic and
anti-idiotypic antibodies, and tumor cell lysates.
The development of immunotherapeutic products for
cancer poses unique challenges and opportunities to the
drug development process. In this review, we will outline
FDA’s approaches to evaluating the safety and efficacy of
these products using appropriate immunotherapeutic
products as examples. This review will include discussions
on requirements for product characterization, preclinical
testing and clinical trial design, and clinical safety and
efficacy testing for cancer therapeutic products, including
cellular and gene therapy products. Various ways to com-
ply with the Code of Federal Regulations (CFR) pertaining
to biological therapeutic products (21 CFR 600–680 and
21 CFR 1270–1271) that require the investigational prod-
uct to be well characterized (21 CFR 610), and free from
extraneous material (21 CFR 610.13) and that the prod-
ucts be approved based on clinical determination of safety
and efficacy (21 CFR 314.105) will also be discussed.Review
Chemistry manufacturing and control (CMC)
considerations
Product characterization
Product characterization is the evaluation of quality at-
tributes of the product. A product should be sufficiently
characterized so as to discern changes in product char-
acteristics over time. Characterization of a product with
regard to its critical quality attributes (CQA) and other
quality attributes early in product development will
assist in future comparability studies necessitated by
process/manufacturing changes, thereby enabling faster
product development. Evaluation of the CQA depends
on a thorough understanding of the biology of the inves-
tigational product.
Adequate product characterization may pose extensive
challenges for complex cellular biological products. An
immediate challenge is the inherent biological variability
of cellular products, and the extent to which this vari-
ability can be controlled on a lot-to-lot basis. The chal-
lenges are complicated by the fact that the early
development of cellular products may be based on a yet
incomplete understanding of the biological roles of all
the product components and on the limited information
gleaned from preclinical studies. Here we will discuss,
with appropriate product examples, a way to achieve a
more complete understanding of cell and gene therapy
products including cancer vaccines and immunothera-
peutics, through comprehensive analysis rather than a
minimalistic approach to product characterization. The
assessment of product quality attributes for well-
characterized immunotherapeutic proteins reviewed by
CDER will not be discussed in this review and readers
are encouraged to review FDA guidance documents
published on these topics [5-7].
Early-phase product development
Prior to initiating first-in-human, dose-finding (Phase 1)
clinical studies under an Investigational New Drug
(IND) application, preliminary specifications for product
characterization should be in place. These product re-
lease specifications for immunotherapeutic products are
established based on the IND sponsor’s previous experi-
ence with their product (and similar products, if applic-
able) and include analytical procedures based on CFR
requirements. As product development proceeds, add-
itional, and narrower, specifications for product quality
and manufacturing consistency should be implemented
based on the data obtained (Figure 1). At the time of ini-
tiation of clinical trials intended to support marketing
applications (Phase 3), lot-release and other product
specifications should be based on all information col-
lected during product development, and consistent with
data generated during clinical studies. During the
BLAIND
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Figure 1 Biological product development overview.
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procedures for product testing should be ongoing or
completed.
The regulatory requirements for biological product
characterization include appropriate tests for (1) identity,
(2) purity, (3) safety, and (4) potency. Over the years,
FDA has published a number of guidance documents, to
which the reader may refer for additional detailed infor-
mation [5-9].
Identity
The identity of the final biologic product must be veri-
fied by assays that will identify the product for proper
labeling and will distinguish the product from other
products being manufactured in the same facility (21
CFR 610.14). Some examples of potentially useful targets
for identity assays include cell surface markers, major
histocompatability complex (MHC) antigen markers,
gene expression, genetic polymorphisms, secreted mole-
cules, and peptide sequences.
Identity assays should be specific and indicative of the
nature or composition of the biological product. As an
example, the use of T cell surface molecule CD4 will, by
itself, be an insufficient T cell product marker given the
current understanding in the field of immunology that
CD4+ T cells encompass a wide array of effector popula-
tions. For example regulatory T cells (Tregs) are a subset
of CD4+ T cells that also express FoxP3 and CD25, and
could be detrimental components of a cancer immuno-
therapy product designed to elicit an anti-tumor
response. Differences in the cellular sub-populations
would not be obvious if the lot release was based on a flow
cytometry assay that only enumerates the number of
CD4+ cells. Additional information like the specificity of
the CD4+ cells, and the population of memory or effector
T cell sub-populations included in the product might also
be important for final product characterization. Due con-
sideration should also be given to minority cell popula-
tions in the final product as a purity measurement as
discussed in the next section. If the acceptance criterion
is based on the percentage of CD4+ T cells in a product,ascertainment of the phenotypic profiles of the remaining
cells could provide additional important information on
product characterization.
There are different considerations for the adequate
identification of non-cellular immunotherapeutic prod-
ucts. For example, tumor antigen preparations encom-
pass a wide variety of agents capable of interacting with
the immune system to produce local inflammation, de-
layed type hypersensitivity reactions and ideally thera-
peutic effects such as tumor regression. Peptide and
protein antigens designed to elicit direct immune
responses against TAAs, have been used either alone, as
conjugates with an immunogenic carrier protein
(immunoconjugates) or as an integrated part of fusion
proteins. Identification of these types of products
includes evaluation of their primary, secondary and
tertiary structures. Ideal peptide, protein, and immu-
noconjugate cancer vaccine therapeutics would include
molecules where the size, structure and function can be
well-controlled, and the upper and lower acceptance
limits can be established and achieved in a consistent
and reproducible manner.
Purity
Product purity (21 CFR 610.13) testing includes assays
for pyrogenicity/endotoxin and for contaminants such as
unintended cell populations (e.g., distinguished by phe-
notypes), residual proteins or peptides used to stimulate
or pulse cells, and materials used during the manufac-
turing process, such as cytokines, growth factors, anti-
bodies, and serum in cell therapy products or residual
solvents in peptide vaccines. Acceptance criteria should
be established for known impurities; for example, limits
should be set for unintended cell types in the final
cellular product.
Biological products intended for injection must be
tested for pyrogenic substances (21 CFR 610.13(b)).
Endotoxin testing using the Limulus Amebocyte Lysate
(LAL) assay method has been successfully used in a
number of early-phase clinical trials. Samples for purity
testing should be taken from the final product, i.e.,
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mend that an endotoxin acceptance criteria be set at or
below 5 EU/kg body weight/hr for parenteral drug,
except that intrathecally administered drugs have a limit
of 0.2 EU/kg body weight/dose [10].
Viability
A minimum viability release criterion should be
established for cellular immunotherapeutics. FDA’s guid-
ances [11] recommend that this specification be at least
70% for products administered by the intravenous route
of administration. If this level cannot be achieved, data
should be submitted to support an appropriate level.
Acceptance criteria for the final product should include
specifications for the total number of viable cells and
cellular sub-populations with documentation to support
safety of the proposed cell number/dose.
Potency
Potency is defined as “the specific ability or capacity of
the product, as indicated by appropriate laboratory tests
or by adequately controlled clinical data obtained
through the administration of the product in the manner
intended, to effect a given result” (21 CFR 600.3(s)).
FDA has published a guidance [12] for cellular and gene
therapy (CGT) products to be administered under an
IND or marketed under a Biologics License Application
(BLA), which includes recommendations for developing
tests to measure potency.
Potency assays, along with a number of other assays,
are performed as part of product conformance testing
(includes in-process, drug substance, and final product
tests), comparability studies [13], and stability testing
[14]. Potency measurements are used to ensure that only
product lots that meet defined specifications or accept-
ance criteria are administered during all phases of
clinical investigation and following market approval.
FDA recommends that manufacturers collect sufficient
product characterization data (i.e., molecular, biochem-
ical, immunologic, phenotypic, physical and biological
properties) throughout preclinical and clinical develop-
ment to provide support for the relevance and appropri-
ateness of the chosen potency assay(s).
Ideally, a validated potency assay should be appropri-
ately designed for each product based on a defined
biological effect that closely reflects the proposed mechan-
ism(s) of action/clinical pharmacodynamic response. FDA
regulations allow for considerable flexibility in determin-
ing the appropriate measurement(s) of potency for each
product. Because of the complex nature of CGT products,
FDA recommends an incremental approach to the imple-
mentation of potency tests. FDA realizes the potency assay
may change significantly during product development. It
is scientifically challenging to identify appropriate potencyassays for cell-based immunotherapeutic products since
the active ingredient is often composed of whole cells and
the activity of these products can generally not be attrib-
uted to one specific cell characteristic. It may be scientific-
ally challenging to identify appropriate potency assays for
cell-based immunotherapeutic products, for example, if
the active ingredient is composed of a mixed population
of cells and the activity of these products can't be attrib-
uted to one specific cell characteristic. FDA thus encour-
ages IND sponsors to develop multiple assays at early
stages of product development, so that as experience with
a product accumulates, the sponsor has greater flexibility
to select the assay(s) most indicative of potency. A timely
discussion with the FDA review team is recommended as
one designs, evaluates, and validates potency assays.
No single potency assay can adequately measure the
CGT product attributes that will predict clinical efficacy.
In general, the evidence of clinical efficacy is obtained
from adequate and well-controlled investigations con-
ducted with a consistently manufactured product, as
specified in 21 CFR 314.126(d). Efficacy data from well-
controlled clinical investigations suggests that a product
has biological activity and thus is potent. Clinical data may
be used to establish a correlation between biological activ-
ity and a more practical potency assay that can be used for
lot release, stability, and/or comparability studies.
The potency of cell-based immunotherapeutic prod-
ucts can be measured using in vitro or in vivo tests, or
both. For complex products consisting of more than one
active ingredient (e.g., cellular tumor vaccines), FDA
may require more than one assay to demonstrate the
potency of each ingredient.
FDA recommends that a manufacturer collect sufficient
product characterization data (i.e., molecular, biochemical,
immunologic, phenotypic, physical and biological proper-
ties) throughout preclinical and clinical development that
may provide support in developing an appropriate potency
assay. Initial exploratory studies may help in assessing
which product attribute(s) best correlate(s) with potency.
Many CGT products are multifaceted and have incom-
pletely characterized mechanisms of action (MOA),
making it difficult to determine essential product quality
attributes, including potency. The MOA for CGT prod-
ucts may be dependent on more than one active ingredi-
ent (e.g., multiple cell types, multi-epitope vaccines).
The traditional approach for assessing the potency of
biological products is to develop a quantitative biological
assay (bioassay) that measures the activity of the product
related to its specific ability to effect a given result. Bioas-
says can include in vivo animal studies, in vitro cell culture
systems, or any combination of these. In cases where de-
velopment of a suitable bioassay is not feasible, a surrogate
measurement can be substantiated by showing a correl-
ation with relevant product-specific biological activity. As
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to establish a correlation between biological activity and a
more practical potency assay that can be used for lot
release, stability, and/or comparability studies. For many
cases, a single biological or analytical assay may not pro-
vide an adequate measure of potency; FDA encourages
developing complementary assays that measure different
product attributes associated with quality, consistency and
stability. These complementary assays might consist of a
combination of biological assays, biological and analytical
assays, or analytical assays alone [15].
FDA regulations require that product characterization
for biologic products, as described in a BLA, include one
or more validated potency assays. Numerous resources
are available for analytical methods validation [16,17].
The validation process identifies potential sources of
error and quantifies them within the assay method. The
validation of the potency assay should include accuracy,
precision (repeatability, intermediate precision), specifi-
city, linearity and range, system suitability, and robust-
ness. It is critically important to apply sound and
appropriate statistical methods to the design and analysis
of potency measurements. A timely discussion with the
FDA review team is highly recommended as one designs,
evaluates and validates potency assays.
Late-phase product development
Late-phase product development typically involves the
manufacture of the test article for evaluation in multi-
center clinical trials that involve a few hundred to a few
thousand study subjects. For this reason, product manu-
facturing is scaled up for the Phase 3, hypothesis-testing
trials and for the potential marketing of the product, as
changes are more easily addressed at this stage than after
the conduct of Phase 3 clinical trials. Introduction of
manufacturing changes following the conduct of Phase 3
clinical trials establishing clinical safety and efficacy may
result in a need to bridge between the product used in
clinical trials and the “to-be-marketed” product. Such
bridging may include preclinical and clinical comparabil-
ity studies that are necessary to support, thus delaying,
the BLA. The most frequently encountered issues with
production scale-up pertain to: 1) changes of manufac-
turing facilities, 2) changes of equipment related to
growth, processing, and storage and 3) process changes.
A change in manufacturing facilities requires a re-
evaluation of the facilities with reference to prevention
of microbial contaminations, flow of materials, and
personnel. Equipment changes are common as equip-
ment used for small clinical trials may not be suitable
for large scale manufacture. Changes in equipment may
be closely related to a need for process changes; for ex-
ample, while sucrose centrifugation-based viral vector
processing may be sufficient for a small exploratoryclinical trial, it may not be practical for the amount of
product needed in a confirmatory trial. In another ex-
ample, the use of different filters in the purification
process may lead to a need to reevaluate the leachables
and extractables profile. Process changes in general can
result in changes in the impurity profile of the product
(e.g., host cell proteins, residual host cell DNA), requir-
ing further changes in the manufacturing process. Add-
itionally, changes in production timing may lead to the
introduction of intermediate storage steps in the manu-
facturing cycle, which may require additional tests for
stability and sterility. While these examples of manufac-
turing changes may not be exhaustive, all manufacturing
changes will require evaluation of both their immediate
(e.g., changes in impurities profile) and downstream ef-
fects (e.g., changes in immunogenicity of the product).
For these reasons, FDA recommends that the IND spon-
sors contact FDA’s product review offices (OCTGT or
OBP, as appropriate) prior to implementing substantive
manufacturing changes and prior to the initiation of
Phase 3 trials intended to establish safety and efficacy
for a marketing application.
Although complete identity and potency tests are not
required during the early stages of immunotherapeutic
product development, they are required prior to initi-
ation of Phase 3 studies. To support late-phase biological
product development, identity, purity, and potency as-
says should be established during the early clinical trials
(Phase 1 and 2). The removal of all in-process reagents,
ancillary factors such as cytokines, growth factors, anti-
bodies, or enzymes to acceptable levels should either be
validated or specifications set for maximum acceptable
limits before the initiation of Phase 3 trials. Stability data
to support the proposed dating period for Phase 3 clin-
ical studies should also be available at this time. The sta-
bility program should address identity, purity, and
potency of the product and intermediates during storage,
and should be initiated as soon as possible in order to
provide real time stability data for products where an ex-
tended dating period is desired. The integrity of the
product could include measurement of viability and
phenotype of cellular products. FDA also recommends
that an end-of-phase 2 meeting be scheduled with the
Agency to identify and discuss all outstanding chemistry,
manufacturing and control issues for the product.Control of product variability
Product variability is inherent in biological products
and the variability has to be controlled, with the
knowledge that as the manufacturing process evolves
through various phases of the clinical evaluation and
manufacturing scale-up, the product may manifest
changes.
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In addition to changes in the product resulting from
changes to the manufacturing process or growth condi-
tions discussed above, product changes may also be
introduced by the starting materials, and reagents. To
control change, vendor qualifications should be built
into the quality assurance and quality control (QA/QC)
program early in the product development cycle [11].
The safety of raw materials and reagents should be
ensured prior to introduction into the manufacturing
stream. Strategies for the control of product heterogen-
eity have to be developed and product should be tested
regularly during development. Assessment of change
should include a comparability study conducted using
well characterized reference materials.
Procedures used in manufacture should be refined
during early-phase studies, but the manufacturing
process should be well established prior to initiating
Phase 3 studies, and changes to the process should be
minimized once the Phase 3 trials are initiated. Changes
in manufacturing during or after the Phase 3 studies will
require demonstration of product comparability, which
may include preclinical and or bridging clinical studies.
Reference materials
Reference materials (RMs) are used for assay develop-
ment and assay validations. One type of RM is a product
sample that is well characterized with reference to its
essential quality attributes. Frequently these reference
samples are products from early production lots, that
have been extensively evaluated by appropriate analytical
methods (e.g., analysis for cell surface markers, cell
number, viability), and biological methods (e.g., bio-
logical function assays such as immunogenicity, tetramer
binding, viral titer, etc.). When qualified assays are used
to evaluate a product from an early production lot, that
product may in turn be used as an in-house reference
material for purposes such as evaluating product com-
parability after manufacturing changes or product scale-
up during later phases of the product development cycle.
In such cases it is essential that there be sufficient prod-
uct manufactured for the specific purpose of use as a
reference material. Biological RM rederived from a RM
may pose a risk of “product drift” with each successive
lot, that while in themselves may remain within their
product specifications, could constitute a large and un-
acceptable variant from the original product. To ensure
that a RM continues to be valid, a RM re-verification
process to demonstrate that a RM is still fit for this
purpose should be established [18] .
FDA continues to actively participate in reference method
development activities and liaise with standard setting
organizations such as American Society of Testing and
Materials International Organization of Standardization,American Type Cell Collection, and other organizations
(e.g., World Health Organization, International Conference
on Harmonization, National Institute for Biological
Standards and Control) to promote good manufacturing
practices and provide methods and reference materials for
testing and analyses that support characterization of
biological products [19,20]. Biological reference materials
are complex and are affected by various parameters,
such as growth and storage conditions, and thus require
characterization that is based on their intended mode of
action. A limited number of cell substrate and viral refer-
ence materials are currently available from ATCC [21,22].
Adjuvants
Vaccine adjuvants are constituent materials (21 CFR
610.15) that are evaluated in combination with an anti-
gen and used to potentiate or augment immune
responses to the target antigen. There are two adjuvants
that are in use in FDA-approved vaccines: aluminum salts
including aluminum hydroxide, aluminum phosphate, and
alum (potassium aluminum sulfate), and ASO4, a mixture
of aluminum salts and monophosphoryl lipid A (MPL)
used in the FDA-approved cervical cancer vaccine
Cervarix. Examples of aluminum salt adjuvanted vaccines
include DTaP vaccines, pneumococcal conjugate vaccine,
and hepatitis B vaccines. Vaccines containing aluminum
salt adjuvant have a demonstrated safety profile with over
six decades of use and have only uncommonly been asso-
ciated with severe local reactions. In view of the number
of aluminum salt containing vaccines that have become a
part of standard childhood vaccination regimens, FDA has
specified a limit to the amount of aluminum in vaccines of
0.85 mg/dose with some exceptions (21 CFR 610.15).
A number of prophylactic and therapeutic cancer
vaccines undergoing evaluation in clinical trials are admin-
istered in conjunction with newer adjuvants such as MF59
(Oil-in-water emulsion), [23] saponin-based adjuvant QS21
[24], and adjuvants with microbial derivatives: AS15,
containing MPL, QS21, CpG and liposome [25] . There is
also interest in the use of human cytokines and growth
factors, which are licensed for the treatment of various
disease conditions, as potential adjuvants. Examples of
approved cytokines and growth factors include IL-2
(aldesleukin [26]), GM-CSF [(granulocyte-macrophage
colony stimulating factor (sargramostim)], and erythropoi-
etin alfa. In addition, other cytokines and cytokine
blockers aimed at redirecting immune responses are also
currently being evaluated as adjuvants for immunotherapy
applications [27] .
As constituent materials of the final product, adjuvants
must meet generally accepted standards of purity and
quality. A change in adjuvant during clinical develop-
ment may constitute a change in product requiring a
new IND. The FDA recommends contacting appropriate
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considering such changes.
General considerations and tests required during all
stages of product development
Licensed biological products must meet specifications
for appearance, identity, purity, safety, and potency.
These product attributes are characterized and refined
throughout product development. FDA approves BLAs
based on substantial evidence of effectiveness and
reasonable assurance of safety for the product’s intended
use. While efficacy of the product is primarily estab-
lished in clinical studies, an assurance of product safety
is required during all stages of both clinical and product
development. The following section explores product
safety testing requirements for the clinical evaluation of
investigational products.
Safety testing and acceptance criteria
Required product testing to assure the safety of bio-
logical products includes tests for (1) sterility, (2) myco-
plasma, (3) adventitious viral agents, and (4) general
safety. These tests are discussed in detail below and are
described in Title 21 CFR Parts 211 and 610 and in FDA
guidance documents. Final product release specifications
for safety are required for all phases of IND submission.
However, actual tests (such as the use of rapid microbial
detection tests for sterility) and specifications may evolve
during product development. Specifications used for
product intermediates should also be reported, as appro-
priate to the IND. In addition to the final product test-
ing, in-process testing can provide meaningful insights
into safety of the final product, particularly for cellular
products that have a short shelf life. All specifications
should be clearly described in the IND submissions, and
a tabular format should be used as appropriate.
Sterility
Sterility (bacterial and fungal) testing on the final prod-
uct should be performed according to the requirements
in 21 CFR 610.12. A 14-day direct inoculation test
method as described in the United States Pharmacopoeia
(USP) <71> is typically used to evaluate sterility of cellu-
lar immunotherapeutics. Alternatively, an automated
detection or other method may be used if validated
appropriately. As antibiotics present in cell culture test
samples may confound sterility results, bacteriostasis
and fungistasis testing (as described in USP <71>)
should be performed to ensure that any residual anti-
biotic does not interfere with the sterility testing.
Samples for sterility testing should be obtained after
final product manipulation, i.e., after all washing proce-
dures, and, preferably, as the final formulation. If the
product is frozen prior to use, samples for sterilitytesting should be taken prior to cryopreservation. If the
product is manipulated by washing, culture, etc. after
thawing, or at any other time (e.g., after transport to the
study site), the IND sponsor should repeat the sterility
testing. In general, a “no growth” acceptance criterion is
used for release of cellular products.
In contrast to other immunotherapeutic products, the re-
sults of a full 14-day sterility assay on the final cellular
product may not be available prior to administration of the
product; therefore, a sample including both cells and super-
natant should be taken for sterility testing approximately
48–72 hours prior to the final harvest (or coincident with
the last re-feeding of the culture). An interim reading of
this sterility test at the time of product release will contrib-
ute to a sterility determination. A rapid microbial detection
test, such as a Gram stain, should also be performed on the
final product prior to administration, and these results will
also contribute to a sterility determination. A sterility test
should also be performed on a sample of the final product,
and both the in-process (48–72 hour) and the final product
sterility test should be continued for the full 14–day cul-
ture. Additionally, a positive sterility test action plan should
be submitted that documents procedures to follow in the
event that either of the 14-day sterility tests reveals that a
contaminated product was administered to a patient. These
procedures should include: physician and patient notifica-
tion, identification and sensitivity testing of the contamin-
ant, additional patient monitoring, investigation to
determine potential sources of the contamination and cor-
rective actions, and reporting of the incident to the IRB and
FDA as an adverse event within 15 calendar days.
Mycoplasma
If product manufacture includes cell culture of more than
24 hours, the product should be tested for mycoplasma
contamination. Mycoplasma testing should be performed
on samples (including both cells and supernatant) obtained
prior to final manipulation (i.e., on cells still in conditioned
culture medium, before final harvest and wash). For the
recommended testing procedure description, refer to the
appropriate FDA guidance document [9]. For products that
must be administered before obtaining mycoplasma
culture test results, alternative rapid mycoplasma detection
assays (e.g., PCR based assays) may be performed. For
Licensure, equal sensitivity and specificity between the
rapid assay and culture-based assay must be validated.
Adventitious agents testing
Adventitious agents (AA) are microorganisms that have
been unintentionally introduced into the manufacturing
process of a biological product. All biologically derived
starting materials, including cell substrates, viral banks,
growth media and components such as fetal bovine serum
(FBS) need to be screened and or tested for the presence
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known viral AA (see Table 1). The challenge is to test for
the presence of human or zoonotic viral agents that have
not yet been identified or agents that cannot be assayed by
a reliable test (such as vCJD). In order to ensure that a
product is free from AA, existing guidances emphasize the
need to use multiple strategies and tests such as in vitro
assays, in vivo assays, reverse transcriptase assays, trans-
mission electron microscopy (TEM), as well as sourcing
materials that are known to be free of specific pathogens
(e.g., specific Pathogen Free flock-derived chicken embry-
onic fibroblastic cells; Fetal Bovine Serum sourced from
BSE free countries). A number of specific assays have been
developed to detect many known viruses in cell substrates,
end of production cells and final product (e.g., ELISA and
NAT based assays such as PCR, qPCR, antibody produc-
tion tests). A number of non-specific assays are also
employed in assaying for the presence of unknown viruses
in cell substrates such as cell co-culture tests, and genome
and transcriptome analysis approaches. Among the non-
specific assays that have been successfully employed to
detect viruses in final products is the whole genome high
throughput sequencing approach that led to the detection
of Porcine Circovirus DNA-1 in vaccine preparations [28].
A general safety test performed by injecting guinea pigs
with the investigational agent is also required (21 CFR
610.11) as a lot-release test for marketed biologic prod-
ucts. If it is impractical to include this general safety test
in release testing, the FDA can grant exemptions to this
test requirement as provided for under 21 CFR 610.11(g).
Preclinical evaluation
General considerations for the preclinical assessment of
immunotherapy products
Considering the range and complexity of immunotherapeu-
tic products, no single preclinical program encompasses
adequate evaluation of potential toxicities associated withTable 1 A list of viral agents that should be tested in
human cell lines used to manufacture cancer
immunotherapeutic products










Specific Viruses (e.g., Bovine and Porcine Viruses)the administration of every immunotherapeutic product in
humans. Therefore, FDA has adopted a scientific data-
driven, case-by-case approach to assess the safety of these
products. This section will discuss some general principles
for the preclinical evaluation of immunotherapeutic
products, followed by a more detailed discussion of selected
immunotherapeutic product types.
The overall goal of the preclinical studies for immuno-
therapeutic products is the same as that for other types of
products: to provide data to support the safety of an investi-
gational product in humans by defining its toxicological
and pharmacologic characteristics. Safety concerns for
these products can exist at multiple levels, including those
that are related to the product (e.g., the replication of a viral
vector in vivo or autoimmunity due to a high homology
between an immunogenic epitope and an endogenous
target), the process (e.g., the introduction of adventitious
agents, or cell transformation due to ex vivo manipulation),
and the biological function (e.g., polarization of the immune
system, or overstimulation of the immune system due to
immunomodulation). Data from in vitro and in vivo pre-
clinical studies, conducted in conjunction with appropriate
product characterization testing, help determine an accept-
able safety profile for an immunotherapeutic product.
Federal regulations require the submission of “adequate
information about the pharmacological and toxicological
studies … on the basis of which the sponsor has concluded
that it is reasonably safe to conduct the proposed clinical
investigations.” The regulations further stipulate that “the
kind, duration and scope of animal and other tests required
varies with the duration and nature of the proposed clinical
investigations” [21 CFR 312.23 (a) (8)]. Practically, preclin-
ical studies conducted to support immunotherapeutic
product development serve to: 1) identify potential target
organs/tissues of toxicity and determine if these toxicities
are reversible; 2) identify an appropriate starting dose level
and inform the dose-escalation scheme and the dosing
regimen of a first-in-human trial; and 3) identify parameters
for safety and activity monitoring in humans.
To achieve these objectives, the conduct of in vitro and
in vivo studies designed to define and understand the
pharmacological properties of the immunotherapeutic
product are an important first step. These proof-of-concept
studies, together with prior knowledge of the targeted
immune pathway and of related or similar products, help
address several objectives: 1) establish a scientific basis for
conducting a specific clinical trial, 2) determine a minimal
pharmacologically effective dose level and immunization
regimen, 3) characterize a potential dose–response relation-
ship, 4) optimize the route of product administration, and
5) provide the basis for the animal species or animal disease
model(s) used for further preclinical testing. Characterizing
the humoral and cellular immune response in animals
exposed to the immunotherapeutic product, with or
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objectives. The immune system, in general, is designed to
respond quickly to internal and external stimuli. Thus
products targeting the immune system can have rapid and
unintended effects. For example, a change in the concentra-
tion of an immunomodulatory agent can have several
different effects on cells. Therefore, it is important for the
animal studies to include adequate evaluation of the
immune response to the administered product. In addition,
correlation of an immune response with functional
outcome, such as an anti-tumor response, improvement of
disease status, or improved survival, in a tumor-bearing
animal model is desired.
The primary objective of the toxicology studies is to iden-
tify potential adverse findings resulting from administration
of biologically active dose levels of the immunotherapeutic
product. Many preclinical studies are conducted to support
a first-in-human clinical trial. Thus, understanding the
relationship between dose level and toxicity in these early
studies, if any, is important, as these data will help establish
a safe starting dose level, dosing route, dosing schedule,
and dose-escalation scheme for a clinical trial. This infor-
mation can also help define subject eligibility criteria and
determine appropriate clinical monitoring following
product administration. The toxicology studies will include
traditional endpoints, such as mortality, clinical observa-
tions, body weights, clinical pathology, and histopathology.
Each endpoint provides insight into the safety profile of the
immunotherapeutic product. For example, clinical path-
ology, which may include serum chemistry, hematology,
coagulation, and urinalysis parameters, is a nonterminal
assessment of the functional status of major organ systems.
Histopathology evaluation, including local tissue reactivity,
is a terminal analysis that can further evaluate both organ
function and architecture, as well as potentially provide
some understanding as to the mechanism of any toxicities
observed. Depending on the type of immunotherapeutic
product under investigation, additional endpoints, such as
toxicokinetics or immunotoxicity, may be included in
general toxicology studies or assessed in independent
studies to address potential safety concerns. Additional
studies, such as developmental/reproductive toxicology
studies, may be needed as the immunotherapeutic product
progresses to late-stage clinical trials, or if there are signifi-
cant modifications to the immunotherapeutic product.
Basic study design considerations can also greatly
enhance the quality and interpretation of the resulting
preclinical data. To the extent possible, a nonbiased study
design incorporating elements such as randomization of
study animals according to a prespecified method, and
assessment of certain study parameters, such as histopath-
ology, is important. Other important design features
include: 1) adequate numbers of animals for statistical ana-
lysis, 2) appropriate control groups, 3) multiple dose levelsof the immunotherapeutic product, 4) a dosing regimen
and route of administration similar to those planned for
the clinical trials, and 5) adequate study duration to allow
for comprehensive assessment of potential adverse find-
ings. The pivotal toxicology studies should be conducted in
compliance with Good Laboratory Practice (GLP)
regulations (21 CFR Part 58), to assure study integrity.
The interpretability of the resulting pharmacology and
toxicology data depends on the biological relevance of the
animal species used. The immunotherapeutic product
should be pharmacologically active in the species, and the
target antigen expression pattern should be similar between
animal and human. When administration of the investiga-
tional product in various animal species will not yield
informative data, use of an animal analogue may be appro-
priate. Toxicology studies are generally conducted in
healthy animals that usually offer the advantages of exten-
sive historical control data and availability of sufficient
numbers of animals. A ‘hybrid’ study design, using an ani-
mal model of disease, that incorporates both activity and
safety endpoints in a single study can, however, sometimes
be a more informative approach, and has been applied to
preclinical evaluation of some immunotherapeutic prod-
ucts. Consultation with the appropriate center (CBER or
CDER) and division within the FDA to discuss the appro-
priate animal species and models to use in a preclinical
testing program for a specific immunotherapeutic product
is encouraged.
Preclinical program designs for specific
immunotherapeutic products intended to treat cancer
Small molecule and biotechnology-derived pharmaceuticals
In general, requirements for the preclinical evaluation
of small molecule or biotechnology-derived products
specifically targeting the immune system and/or its
regulation are the same as for other small molecule or
biotechnology-derived products with non-immune
targets. As a starting point, toxicology studies should be
conducted in two species, one rodent and one non-
rodent. If these standard studies are unlikely to yield
relevant data, other approaches might be justifiable. For
example, for many biologic products, such as monoclonal
antibodies, there may be no relevant rodent species; thus,
a single non-rodent species for toxicological evaluation
may be justified. For the development of pharmaceuticals
targeting the immune system for the treatment of cancer,
the guidelines outlined in the International Conference
on Harmonisation (ICH) Guidances for Industry S9:
Nonclinical Evaluation of Anticancer Pharmaceuticals and
S6: Preclinical Safety Evaluation of Biotechnology-Derived
Pharmaceuticals, the S6 Addendum should be followed
[29-31] . In addition, some consideration may be given to
the ICH S8 guidance on immunotoxicity [32] . While this
guidance is specifically concerned with unintended
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by drugs, some of its recommendations may also be rele-
vant to pharmaceuticals designed specifically to modulate
immune function and may give developers an idea of the
kinds of evaluations which would be useful to regulators.
Many of the evaluations described in this guidance can be
incorporated into standard toxicity studies, including
detailed immunophenotyping and assessments of cytokine
release following product administration. In addition, a
potential strength of nonclinical evaluation of products
with immune targets is the relative ease of obtaining pri-
mary human cells for in vitro testing. Immune assays
using relevant primary human cells can serve as valuable
tools for the prediction of potential toxicity, with results
from these assays being used as indicators of both the
primary clinical effects of the product and the relevance of
the animal species used in toxicology studies. In addition,
effects of a product on the function of primary human
cells can be used in conjunction with traditional animal
studies for the estimation of a minimally anticipated
biological effect level (MABEL). The idea of the MABEL
has been accepted under ICH S9 as a potentially useful
measure for establishing an acceptable starting dose level
in clinical oncology trials investigating products with
immune agonistic activity, especially in cases where there
is little experience with the targeted pathway or no
relevant animal model. Other approaches to set a starting
dose level may be acceptable as well.Cell-based immunotherapeutic products
Many immunotherapeutic products are cell-based, and
include autologous or allogeneic dendritic cells, natural
killer (NK) cells, T cells, and tumor cells. A safety con-
cern for some of the cell-based immunotherapeutic
products is uncontrolled proliferation in vivo. A recent
example is the persistence in situ of K562-GM-CSF cells
(GM-CSF-expressing human leukemia cell line) after
subcutaneous administration in humans even though
the tumor cells were irradiated prior to inoculation. The
prolonged expression of GM-CSF from these cells may
have contributed to the leukocytosis observed in the pa-
tient [33]. In another case, following infusion in patients,
the T cells expanded approximately 1000-fold or more,
with concomitant significant increase in proinflammatory
cytokine levels, and associated adverse effects [34]. Thus,
preclinical studies for these products should assess the
proliferation status and the potential for clonality of the
cells through in vitro and/or in vivo testing. In addition,
administration of a cytokine with a cell-based immuno-
therapeutic product may affect the in vivo function and
safety of the cell-based product. The potential for such
interactions should be considered when designing
preclinical studies.Gene-based immunotherapeutic products
Gene-based immunotherapeutic products include tumor
antigens co-expressed with various transgenes such
as cytokines and costimulatory factors, delivered by
plasmid DNA, viral vectors, or microorganisms. This
product class also includes genetically modified cells.
The safety and potential efficacy of these products is
influenced by the vector and by the expressed transgene
(s). For example, in a clinical study evaluating the use of
ex vivo engineered T cells for renal cell carcinoma,
immune responses were detected to both the chimeric
antigen receptor (CAR) and to the retroviral vector.
These immune responses may have influenced the
observed limited in vivo persistence of these CAR T cells
[35]. Use of vectors that are constructed of a retroviral or
lentiviral backbone may result in insertional mutagenesis,
which raises tumorigenic concerns for some genetically
modified cells, especially when these cells are expected to
persist in vivo for a long time. In addition to the preclinical
studies conducted to determine the in vivo safety of the
administered vector and of the expressed transgene(s),
characterization of the biodistribution profile of the vector
to confirm its presence at the desired therapeutic sites(s), as
well as its absence in non-target tissues, is important [36].
Therapeutic vaccines
The therapeutic vaccines discussed in this section
consist of the conventional tumor associated antigen
(TAA)-derived vaccines, such as synthetic peptides,
purified recombinant antigen-based proteins, anti-tumor
idiotypic antibodies, conjugated antigens, and tumor
lysates. These antigens are used to induce an immune
response against the tumor. Potential safety concerns
include local inflammatory reactions, systemic toxicity,
adverse effects on the host immune system, and auto-
immune responses, which can be caused by impurities,
contaminants, or the components of the vaccine formu-
lation. Preclinical studies should be designed to address
these concerns [37]. The selected antigen may be
present only in the tumor cells (e.g., tumor-causing viral
proteins or mutant proteins in tumor cells), which is de-
sired, or it may be differentially expressed in tumor cells
versus normal cells (e.g., cancer/testis antigens, CEA,
and Her2/neu). An immune response to a tumor antigen
is expected after immunization; however, a similar im-
mune response to the same antigen in normal cells poses
a potential safety issue. In addition to evaluation of this
safety concern in animals when feasible, data generated
from a tissue expression profile analysis can provide valu-
able information as to the possible normal tissues/organs
that the selected antigen may also target. Thus, such an
analysis can help determine subject eligibility criteria, as
well as aspects of the clinical monitoring plan. Finally, the
preclinical program for a therapeutic vaccine that may be
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ate the activity and safety of the vaccine-adjuvant
combination.
Use of adjuvants in combination with immunotherapeutic
products
An adjuvant is an agent that augments or directs the
specific immune response to an antigen (in this case, the
immunotherapeutic product). It is often co-mixed or co-
administered with the antigen to induce a more robust
immune response. Adjuvants act through diverse mecha-
nisms, such as creating an antigen repository effect,
interacting with specific innate immune pathways, and
serving as ligands for different pattern recognition recep-
tors. There are many different forms of adjuvants, includ-
ing traditional aluminum salts (e.g., aluminum hydroxide,
aluminum phosphate), lipopolysaccharides and their deriv-
atives, cytokines, CpG oligodeoxynucleotide, and others.
The adjuvant used determines, to some degree, the
general type of immune response that will be generated by
the immunotherapeutic product. Therefore, data to sup-
port the rationale for the adjuvant selected is important.
Potential toxicities may be caused by the administration of
the adjuvant alone (e.g., induction of hypersensitivity and
autoimmunity; induction of proinflammatory effects), or
by possible additive or synergistic effects when given in
combination with the immunotherapeutic product. There-
fore, preclinical testing should include the assessment of
the safety and activity of the immunotherapeutic product
alone, the adjuvant alone, and the immunotherapeutic
product in combination with the adjuvant, administered
according to the planned clinical immunization regimen
and route of administration. For general principles regard-
ing preclinical considerations for adjuvants in therapeutic
vaccines, refer to the European Medicines Agency
document ‘Guideline on Adjuvants in Vaccines for
Human Use; January 2005 [38] .
Clinical development and statistical assessment plans
Immunotherapeutic products, specifically monoclonal
antibodies, have become part of the standard armament-
arium of the practicing oncologist, with numerous indi-
cations and products licensed by FDA and international
regulatory agencies. Therapeutic cancer vaccines utiliz-
ing active immunity have proved more challenging to
develop, and to date only one product and therapeutic
indication has been licensed by FDA. It is hoped that an
understanding of the events generating and regulating
tumor immunity will result in more licensed active
cancer immunotherapies [39]. This section will address
clinical trial designs, clinical safety, and clinical efficacy
testing for cancer immunotherapeutic products. Adop-
tive immunotherapeutic products which may mediate
their therapeutic effect by targeting the tumor directly,such as T cell or NK cell products, have unique chal-
lenges in terms of their clinical study design and safety
monitoring. A detailed discussion of the clinical consid-
erations of clinical studies for adoptive immunothera-
peutic products is beyond the scope of this review.
Developers of cancer vaccines planning to initiate
studies with adoptive immunotherapeutic products for
cancer should discuss the details of the proposed studies
with the appropriate review division(s).
Considerations for early clinical trials
The primary goals of early clinical trials are to assess the
safety of the product; to determine the recommended
tolerable (Phase 2) dose or optimal biological dose and
dosing schedule for the product; and to identify and
study the potential biological activities to provide
scientific data to guide further product development.
The selection of the starting dose and the subsequent
dose-escalation scheme, as well as the dosing schedule,
for initial clinical trials of a cancer vaccine should be
supported by data generated from the preclinical studies
and/or prior human experience. When feasible, preclin-
ical in vitro and in vivo proof-of-concept (POC) studies
are recommended to provide the rationale for the
proposed clinical trial. The sponsor should provide
comprehensive information in the IND, including any
existing clinical data regarding the activity and safety
profile, to support the safety of the immunotherapeutic
product in the proposed trial. The traditional standard
dose-escalation schedule in the development of cancer
therapeutics uses the so-called “3 + 3 design;” however, a
maximum tolerated dose (MTD) is infrequently identi-
fied for a cancer vaccine. The dose-toxicity curve may
be so flat that the highest dose that can be administered
is limited by manufacturing or anatomic issues rather
than toxicity. In addition, there may be limited informa-
tion from preclinical studies to support a starting dose
for a monoclonal antibody, e.g., when there is no rele-
vant animal model for the targeted antigen; in such situ-
ations, a standard 3 + 3 design may not be appropriate
for first-in-human trials. In these cases, the sponsor may
consider designing the trial to quickly identify a dose of
the monoclonal antibody that is biologically active, while
enrolling the least number of subjects to dose cohort
levels that are inert. Therefore, this 3 + 3 design may
not be the most suitable approach to gathering informa-
tion from early-phase trials of immunotherapeutic prod-
ucts, and alternative trial designs should be considered.
Given the relatively acceptable safety profile of certain
types of cancer vaccines (e.g., peptide vaccines) and the
desire to expose as few patients as possible to ineffective
doses of immunotherapeutic products, alternative dose-
escalation approaches, such as accelerated titration (e.g.,
half-log or two-fold dose-escalation) or continuous
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3 + 3 design. When using such designs, the protocol
should describe acceptable parameters for the dosing
endpoint (supported by data). Irrespective of which
dose-escalation approach is chosen, the study protocol
should clearly define dose-limiting toxicity (DLT), the
subject “off-treatment” criteria, and the study stopping
rules that will ensure subject safety. When no DLT is
expected or achieved, optimization of other outcomes,
such as the immune response, can be useful to identify
doses for subsequent studies.General considerations for clinical trials
Patient population
The conventional model for clinical development of a
chemotherapeutic agent involves initial testing in
patients with advanced/metastatic diseases and different
tumor types to determine the optimal dose, schedule,
and MTD. Once its efficacy and safety are demonstrated
in the setting of metastatic disease, the same agent may
then be developed and tested in subjects who have min-
imal or no evidence of residual disease [40,41]. However,
the time interval from administration of study agent to
subsequent disease progression in patients with meta-
static cancer may be short. This time may be insufficient
for development of an anti-tumor immune response
needed for activity/effectiveness of a cancer vaccine. In
addition, patients with metastatic disease usually have
received multiple treatments (e.g., cytotoxic and/or
immunosuppressive chemo- and radio-therapies) for
their cancer. These therapies may be detrimental to the
immune system, minimizing the potential responsiveness
to the cancer vaccine being tested. In contrast, testing
cancer vaccines in patients with minimal burden of dis-
ease may provide adequate time for the cancer vaccine
to elicit a detectable immune response. However, dem-
onstration of efficacy would require following subjects
for evidence of disease recurrence, which generally re-
quires a randomized setting. Consequently, developers
of cancer vaccines need to weigh the advantages and
disadvantages of testing these agents in patients with
metastatic diseases versus patients with no evidence of
residual disease or minimal burden of disease.
Although it may be acceptable to test heterogeneous
patient populations with a common antigen in early-
phase trials, this approach may not provide interpretable
evidence of efficacy for the purpose of licensure.
Interpretation of trial results from a heterogeneous pa-
tient population can be challenging, and the objectives
of the trials may not be achieved. Thus, in selecting the
patient population for cancer vaccine testing in early
trials, careful consideration should be given to the
heterogeneity of the study population.Monitoring the immune response and immunogenicity
The role of immunogenicity testing in clinical trials is
different during the development of cancer vaccines
than during the development of immunotherapeutic
proteins such as monoclonal antibodies. In cancer
vaccine development, immune monitoring is mainly ex-
ploratory, especially in early-phase trials, with the major
goals to establish proof-of-principle for the proposed
pharmacological effect and to show immunogenicity of
the administered antigens. However, monitoring of the
immune response can be useful for clinical development
of therapeutic cancer vaccines to optimize the dose and
schedule, determine whether the vaccine induces the
intended immune responses, assess immune tolerance,
provide proof-of-concept, and aid the decision-making
process concerning further product development and later
clinical trial design. Mounting a clinically effective anti-
tumor response involves a multi-component process
coordinated to mediate the effect. Therefore, multiple
monitoring assays may be needed to identify and measure
the components of the immune responses. Assay
standardization should include specific parameters to
control for general variability in an immune response
across study sites. The assay parameters, such as assay
conditions, sensitivity and specificity of the assay, any
in vitro amplification step involved, positive and negative
controls, cutoff values for determining the positive and
negative test results from patients’ specimens, and the
statistical analytical methods to be used for the test results,
should be clearly described in the clinical protocol prior to
the initiation of the clinical trial.
In contrast, immunogenicity testing plays a central
role in therapeutic protein development. Beginning with
the first-in-human trial, development programs of immu-
notherapeutic proteins incorporate serial testing—patient
samples obtained pre-exposure, during administration,
and following discontinuation at a time that minimal
interference would be expected from remaining immuno-
therapeutic product levels—to identify anti-product anti-
bodies (APA) and assess any impact that these APA may
have on the safety (e.g., hypersensitivity reactions for
monoclonal antibody products or autoimmunity for
endogenous cytokines), and efficacy of therapeutic
proteins [42]. The appropriate role and timing for immune
response monitoring and immunogenicity is individualized
based on the product characteristics and can be discussed
with FDA.
Co-development of assays and therapeutics
When the proposed mechanism of action involves a spe-
cific antigen or other therapeutic target, consideration
should be given to developing an assay or mechanism to
measure the target antigen expression in tumor tissues
of individual patients and using that information in
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are generally regulated by the Center for Devices
and Radiological Health (CDRH). Therefore, sponsors
developing cancer vaccines who are considering includ-
ing the use of an assay with a specific cancer vaccine,
should request a meeting with both the relevant FDA
product review office and device review division. Discus-
sions begun early in the development process, ideally
before submission of an IND and/or IDE (Investigational
Device Exemption), may help ensure that product
development provides data that establish the safety and
effectiveness of the therapeutic product and assay pair.
Adjuvants used to stimulate immune response
Cancer vaccine formulations may contain adjuvants,
agents that are not generally licensed by themselves but
are used in conjunction with vaccine antigens to aug-
ment or direct the specific immune response to an
antigen. General requirements for inclusion of such
adjuvants in licensed biological products are described
in 21 CFR 610.15. These requirements include submis-
sion of evidence that the proposed adjuvant does not
adversely affect the safety or potency of a given vaccine
formulation. Information supporting the value of adding
the adjuvant should be provided, preferably at an early
stage of vaccine development, and may include evidence
of enhanced immune response or antigen-sparing
effects, and data supporting selection of the dose of the
adjuvant. In general, the use of adjuvants is not subject
to the requirement that the contribution of each compo-
nent be demonstrated (as in the case of “fixed combin-
ation products” subject to 21 CFR 300.50). However,
when products which may have independent clinical
activity (e.g., cytokines) are used as adjuvants to enhance
the effects of vaccine antigens, the study design and con-
trol group(s) should be discussed with FDA. Study de-
sign requirements will be considered on a case-by-case
basis.
Clinical endpoints for cancer immunotherapy studies
One of the most important aspects in designing a late-
phase trial is to choose a clinically meaningful endpoint.
Demonstrable clinical benefits vary with cancer type and
status of disease. Clinical benefits that have supported
drug approval have included important clinical outcomes
(e.g., increased survival, symptomatic improvement) but
also have included effects on established surrogate
endpoints. FDA’s “Guidance for Industry: Clinical Trial
Endpoints for the Approval of Cancer Drugs and
Biologics” dated May 2007, and “Guidance for Industry:
Providing Clinical Evidence of Effectiveness for Human
Drug and Biological Products,” dated May 1998 contain
useful recommendations to be consulted prior to initiat-
ing discussions with CBER regarding the endpoints for alate-phase clinical trial of a cancer vaccine. Improvement
in how a patient feels, as measured by patient-reported
outcome instruments (PRO’s), if properly validated,
could constitute a clinical benefit supporting licensure;
see “Guidance for Industry: Patient-Reported Outcome
Measures: Use in Medical Product Development to
Support Labeling Claims,” dated December 2009. While
these guidances may be helpful, it is important to keep
in mind that endpoints based on radiologic tumor as-
sessments, as discussed in section III.B of the May 2007
guidance, may not be the most appropriate endpoints
for a late-phase clinical trial for a cancer vaccine. Recent
evidence suggests that cancer vaccines may be more
likely to have an effect on overall survival than on other
endpoints such as delay in progression or radiological
tumor response [43].
Disease progression/recurrence immediately or shortly after
the initial administration of immunotherapeutic products
In oncology practice, patients are normally taken off
current treatment when they have disease progression/
recurrence. Because immunotherapeutic products may
need time to elicit or amplify an immune response that
could manifest as biological activity (i.e., a tumor-
specific immune response), a delayed effect can be
expected in the subjects who received the vaccine.
Shortly after the initial vaccine administration, subjects
may experience disease progression prior to the onset of
biological activities or effects from the vaccine (delayed
effects). Therefore, clinical progression may not be a
contraindication to continued administration of immu-
notherapeutic products. One potential approach to this
situation would be for the study protocol to clearly
define situations in which vaccination therapy may be con-
tinued, for example, when there is no deterioration of sub-
ject performance status, subjects continue to meet all
other study protocol eligibility criteria, no DLT has been
observed, and all toxicities resolved to the baseline level.
Concomitant and subsequent therapies
One recent advance in the immunotherapy field is the
realization that effective destruction of a tumor involves
multiple coordinated immune mechanisms. These
mechanisms include, but are not limited to, enhance-
ment of the activities of antigen presenting cells, activa-
tion of effector T cells, and removal of suppressor T
cells. The ultimate therapeutic effect of immunothera-
peutic products may be diminished or enhanced by
other cytotoxic or immunomodulatory treatments.
Therefore, such cytotoxic or immunomodulatory effects
of other treatments should be considered in the clinical
trial design and in the overall product development plan.
In addition, if the development plan includes concurrent
development of two or more novel immunotherapeutic
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requires specific considerations because co-development
would be expected to provide less information about the
safety and efficacy of each individual product. In general,
initial clinical trials should be designed to characterize the
safety and pharmacokinetics of the individual components
—similar to the development program for an individual
drug. The proof-of-concept trials should demonstrate the
contribution of each immunotherapeutic protein compo-
nent to the effect of the combination, if not already suffi-
ciently established during the development program [44].
A compelling biological rationale should support use of
any concomitant therapy (e.g., chemotherapy, biotherapy,
radiotherapy, laser therapy), including the mode of
action, dose and schedule of the concomitant therapy,
and interactions of the concomitant therapy with the
immunotherapeutic product. When standard therapies
are available, consideration should be given to the timing
and sequencing of these therapies, relative to the sched-
ule of immunotherapeutic product administration, to
optimize the evaluation of safety and potential biologic
activities. Preclinical exploration of the different options
of timing and sequencing of immunotherapeutic product
and standard therapy can help guide clinical develop-
ment. Trial design details, including eligibility criteria
and stratification factors, should be carefully considered
in order to minimize the impact of standard therapies on
the study’s ability to detect the immunotherapeutic
product's biological (pharmacodynamic) activity.Statistical issues
The overall clinical effect of an immunotherapeutic
product should be evaluated in the context of the cur-
rently available therapeutic options. Use of a superiority
trial design to demonstrate an immunotherapeutic
product’s treatment effect on a chosen endpoint is
recommended. In certain clinical settings, the effect size
of the available therapy(ies) may be well established. In
these limited situations, a noninferiority (NI) trial design
and analysis may be considered. However, the design of a
NI trial is complex; therefore, early consultation with the
FDA and careful consideration of the recommendations in
FDA’s “Draft Guidance for Industry: Non-Inferiority
Clinical Trials,” dated March 2010 are important.
Adaptive trial designs are considered on a case-by-case
basis. Sponsors should consider the recommendations in
FDA’s “Draft Guidance for Industry: Adaptive Design
Clinical Trials for Drugs and Biologics,” dated February
2010.
Imbalances in subsequent therapies may confound the
interpretation of study results, particularly when the
primary endpoint is overall survival. Therefore, the study
should document the nature and duration of subsequenttherapies, and appropriate sensitivity analyses should be
pre-specified.
To avoid the biases that can be introduced in the
conduct of the trial and in the analyses of the trial results,
trials should have appropriate controls, either an active
comparator or placebo. Studies involving a placebo should
be carefully considered and planned. Withholding an
available therapy with proven safety and efficacy may be
unethical. However, FDA recognizes that single-arm trial
designs may be appropriate in specific situations, such as
clinical trials in patients with refractory cancer with no
available therapy or rare cancers. The sponsors should
consider the limitations of single-arm trial designs.
Blinding of subjects, investigators, and evaluators may
be helpful to decrease the risk of bias in the study results.
However, either cancer vaccines or co-administered
immune stimulatory agents can cause reactions that make
the subjects treated with the vaccine easily identifiable. To
maintain blinding of treatment assignment, the study may
need to provide separate personnel for each of the follow-
ing: study agent administration; post-administration
subject care; and endpoint assessment. For other immu-
notherapeutic products such as monoclonal antibodies,
blinding may be limited due to significant toxicities
associated with the administration of these products.Conclusions
Immunotherapeutic products, including therapeutic cancer
vaccines, monoclonal antibodies, and therapeutic proteins
have become part of the standard treatment options of the
practicing oncologist, with numerous indications and prod-
ucts licensed by FDA and international regulatory agencies.
Many more products are at various stages of development.
To facilitate this development, FDA has organized
workshops on cancer vaccines and cell and gene therapies,
published guidance documents, and organized advisory
committee meetings to discuss scientific issues relevant to
immunotherapeutic products. Most recently, FDA pub-
lished a guidance document for cancer vaccine products
[37]. It is expected that more guidance documents will be
published in the future. With the rapid advances of tech-
nology and medical sciences, new concepts and products
related to cancer immunotherapy will evolve. The practice
of product characterization, preclinical evaluation, and
clinical trial methodology will need to adapt to the advances
in this exciting field in order to facilitate product develop-
ment and better protect the public health. Indeed, many
technologies and new tools like ‘omics technology, data
mining, new analytical assays, stem cell technology, and
others are being developed for the evaluation of product
characterization and safety. FDA remains actively engaged
with the stakeholders in facilitating development of cancer
immunotherapeutics and other products for cancer.
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1Gene therapy products are defined in the 2006 FDA
Guidance entitled Gene Therapy Clinical Trials –
Observing Subjects for Delayed Adverse Events: “Products
that mediate their effects by transcription and/or
translation of transferred genetic material and/or by
integrating into the host genome and that are adminis-
tered as nucleic acids, viruses, or genetically engineered
microorganisms. The products may be used to modify
cells in vivo or transferred to cells ex vivo prior to
administration to the recipient”.
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